Purpura, Thrombocytopenic, Idiopathic Clinical Trial
Official title:
A Phase II, Open-Label, Efficacy and Safety, Ascending Dose, Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura
Verified date | August 2014 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
Status | Completed |
Enrollment | 18 |
Est. completion date | April 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Patients must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form prior to admission to this study. - Patients may be male or female, between the ages of 18 75. Men, if sexually active, must agree to use at least one medically acceptable form of birth control. Women of childbearing potential must have a negative urine pregnancy test, and agree to use two independent methods of birth control, if sexually active. - Patients must have a diagnosis of chronic refractory ITP for at least 3 months. Chronic refractory ITP is defined as: 1. Platelet count < 30,000/mm3 consistently for 3 months (except for transient nonsustained responses to various therapeutic regimens). There must be at least three separate platelet counts (below 30,000/mm3) over this period, with at least one extending back to three months or more prior to patient entry into the study. 2. The following conditions will have been excluded either by history or appropriate laboratory investigation: HIV infection (see below), lymphoproliferative disorders, myelodysplasia, SLE, drug-induced or alloimmune thrombocytopenia, or dysglobulinemias. 3. The patient must have tried at least two typical regimens for the treatment of ITP (George et al., Blood, 1996; Practice Guidelines, American Society of Hematology). At least 50% of the enrolled patients will not be known to be refractory to IVIg. Patients may or may not have been treated with IVIg in the past. - Subjects must test negative for HIV, HBV, and HCV by standard serologic tests within the previous six months. Exclusion Criteria: - Patients who have a history or presence of substantial or clinically significant respiratory, gastrointestinal, renal, hepatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorders that, in the Investigator's opinion, could affect the conduct of the study or the absorption, metabolism or excretion of the study drug are excluded. Specifically excluded are lymphoma/chronic lymphocytic leukemia, hepatitis, or HIV associated with ITP. - Patients who have a history of relevant drug hypersensitivity are excluded. - Patients who have a history of substance abuse, drug addiction or alcoholism are excluded. - Patients with the following laboratory abnormalities: a leukocyte count < 2,500/mm3, a neutrophil count of < 1,800/mm3, lymphocyte count < 750/mm3, Hgb < 10 g/L, or transaminase levels (ALT, AST) > 1.5xULN are excluded. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Cleveland | Ohio |
United States | Research Site | New York | New York |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States,
Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009 Apr 2;113(14):3154-60. doi: 10.1182/blood-2008-07-166439. Epub 2008 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 2 | 2 weeks | No | |
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 6 | 6 Weeks | No | |
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 12 | 12 Weeks | No | |
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 24 | 24 Weeks | No | |
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Month 12 | 12 Months | No | |
Primary | Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Month 24 | 24 Months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01356511 -
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
Completed |
NCT00540423 -
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00372892 -
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
Not yet recruiting |
NCT03252457 -
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
Phase 3 | |
Completed |
NCT00151840 -
Efficacy and Safety of IVIG-L in ITP Patients
|
Phase 3 | |
Recruiting |
NCT05438875 -
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
|
Phase 3 | |
Completed |
NCT02281370 -
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT00547066 -
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
|
Phase 1/Phase 2 | |
Completed |
NCT00370331 -
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
|
Phase 3 | |
Completed |
NCT00828750 -
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00487968 -
Eltrombopag Taste Testing in Healthy Adult Volunteers
|
Phase 1 | |
Withdrawn |
NCT01317966 -
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT03443570 -
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
|
Phase 3 | |
Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
Completed |
NCT02201290 -
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00220727 -
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
|
Phase 2 | |
Completed |
NCT02334813 -
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
|
Phase 3 | |
Completed |
NCT02891109 -
Regulatory B Cells and Chronic Immune Thrombocytopenia
|
N/A | |
Completed |
NCT03258866 -
The Study of Different Dose Rituximab in the Treatment of ITP
|
Phase 4 | |
Completed |
NCT01327872 -
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
|
Phase 1 |